Xianchun Zhou

Dr. Xianchun Zhou

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2026 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
JYJiyu Yang
Jiyu Yang
CWCuixue Wang
Cuixue Wang
JXJian Xue
Jian Xue
XMXiao Ma
Xiao Ma
YHYingze Hou
Yingze Hou
XZXianchun Zhou
Xianchun Zhou
Background: The Prognostic Nutritional Index (PNI) is a critical biomarker reflecting the nutritional and immune status of cancer patients. Its association with the prognosis of various malignant tumors has been extensively investigated. However, a comprehensive systematic evaluation of the prognostic significance of PNI across different cancer types remains limited. Methods: This umbrella review conducted a systematic search of PubMed, Embase, Web of Science, and the Cochrane Library to include meta-analyses that assessed survival outcomes related to cancer across diverse malignancy categories. The quality of the evidence was evaluated utilizing the GRADE and AMSTAR tools. Effect sizes, expressed as hazard ratios (HR) or odds ratios (OR), were synthesized using either random-effects or fixed-effects models. Additionally, analyses of heterogeneity, indicated by I 2 , and assessments of publication bias were performed as appropriate. Results: The Prognostic Nutritional Index (PNI) demonstrates associations across multiple cancer types, with a low PNI significantly linked to poor prognosis in 12 categories of malignant tumors. The HRs for 103 outcomes ranged from 1.15 to 2.98 ( p < 0.05). The overall quality of evidence is predominantly low or very low, as assessed by the GRADE criteria, affecting 89.3% of outcomes. This is largely attributed to heterogeneity (47.8% with I 2 > 50%), publication bias (40%), and limitations in AMSTAR scoring. Notably, 11 outcomes provided moderate-quality evidence, all indicating substantial effect sizes. Specifically, PNI shows significant prognostic value in breast cancer (preoperative overall survival [OS] HR = 2.56, postoperative HR = 2.63), cervical cancer (OS HR = 2.98), and among patients receiving immunotherapy (e.g., lung cancer immune checkpoint inhibitor [ICI] group OS HR = 2.68). Conclusion: A low Prognostic Nutritional Index is consistently associated with poorer outcomes across various cancer types, particularly in predicting responses to immunotherapy. However, due to the current limited quality of evidence, it cannot yet be recommended as a standalone prognostic or decision-making tool across all tumors. Future rigorously designed, multi-center studies are required to validate its clinical utility. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/,CRD42025111093.

25 December 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
YYYang Yang
Yang Yang
XMXiao Ma
Xiao Ma
YLYue Li
Yue Li
LJLihua Jin
Lihua Jin
XZXianchun Zhou
Xianchun Zhou

1 December 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YHYingze Hou
Yingze Hou
CZCan Zhu
Can Zhu
ZSZhean Shen
Zhean Shen
YXYongan Xu
Yongan Xu
SZShiwei Zhou
Shiwei Zhou
XZXianchun Zhou
Xianchun Zhou
Carbon nanomaterials have garnered significant interest from researchers acROSs various disciplines, primarily due to their high specific surface area, versatile surface chemical modifications, and exceptional optical properties. Notable carbon nanomaterials include graphene, carbon nanotubes, and carbon quantum dots, each exhibiting distinct potential applications within the biomedical domain. Extensive research over the years has positioned these diverse carbon nanoparticles as promising candidates for drug delivery, cancer diagnosis and therapy, tissue engineering, and biosensing, among other applications. Nonetheless, the issue of toxicity associated with carbon nanomaterials presents a pressing challenge that necessitates resolution. Empirical studies indicate that the size, aggregation state, and surface functionalization of carbon nanotubes can influence the biotoxicity and immunotoxicity of carbon nanoparticles within biological systems, thereby impacting their clinical translation and application. To advance the application and clinical translation of carbon nanomaterials within the biomedical field, this review will focus on carbon quantum dots, carbon nanotubes, graphene nanoparticles, and other carbon-based nanomaterials. It will provide a comprehensive summary of their application progress in the biomedical sector, as well as an analysis of their biotoxicity and immunotoxic responses. This synthesis aims to facilitate the clinical translation and application of carbon nanomaterials.

3 February 2026 in Drug Delivery
Verified
Journal Article
Open access
YHYingze Hou
Yingze Hou
CZCan Zhu
Can Zhu
ZSZhean Shen
Zhean Shen
DCDesheng Cao
Desheng Cao
LWLiangyu Wei
Liangyu Wei
XZXianchun Zhou
Xianchun Zhou
Mesoporous silica nanoparticles (MSNs) have garnered significant attention across various disciplines, including chemistry, physics, and materials science, owing to their distinctive properties and functionalities. Numerous studies have demonstrated that MSNs possess several advantageous characteristics, such as tunable pore sizes, excellent biocompatibility, and a high specific surface area. These attributes render mesoporous silica nanoparticles promising for diverse applications in medical fields, including in vivo targeting, drug delivery, and disease diagnosis. Nevertheless, recent research has indicated that mesoporous silica may induce cellular and tissue toxicity in humans, necessitating further evaluation of its long-term safety. Additionally, parameters such as the shape, particle size, and surface modification of MSNs require careful control to enhance their biodegradability, regulate the circulation time of nanomaterials within the body, and mitigate the immunogenicity of mesoporous silica, thereby facilitating the clinical translation of mesoporous silica nanoparticles. This article reviews the advancements in research concerning the use of mesoporous silica nanomaterials in targeted therapy, drug delivery, and tissue engineering. This work evaluates the potential applications of mesoporous silica materials in the biomedical sector and delineates future research directions for MSNs by examining and summarizing their biological toxicity and associated risks.

7 December 2025 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
XMXiao Ma
Xiao Ma
LQLinzhuo Qu
Linzhuo Qu
QWQunying Wu
Qunying Wu
QYQingqing Yu
Qingqing Yu
ZLZhenhua Lin
Zhenhua Lin
XZXianchun Zhou
Xianchun Zhou
Ovarian cancer (OC) remains a highly lethal gynecologic malignancy characterized by substantial molecular heterogeneity and diagnostic challenges. Although

12 May 2025 in Breast Cancer Research
Verified
Journal Article
Open access
XMXiao Ma
Xiao Ma
BZBaojian Zhang
Baojian Zhang
XYXuezhe Yin
Xuezhe Yin
SYShiPeng Yang
ShiPeng Yang
ZLZhenhua Lin
Zhenhua Lin
XZXianchun Zhou
Xianchun Zhou
In tumors rich in adipose tissue, angiogenesis is a critical factor in promoting cancer cell metastasis. However, the connection between angiogenesis and the mechanisms driving adipose metabolic remodeling in breast cancer (BC) remains insufficiently understood. This research seeks to explore whether and how CPT1A, a crucial rate-limiting enzyme in fatty acid oxidation (FAO), supports angiogenesis through metabolic pathways in BC. First, cell functional assays and animal models were employed to elucidate the pro-carcinogenic effects of CPT1A on BC and its role in metabolic alterations. Following this, the reciprocal regulatory relationship between CPT1A and HIF-1α was elucidated using transcriptomic studies, ubiquitination analysis, and dual-luciferase assays. Matrigel tube formation assays, vasculogenic mimicry assays, and chick chorioallantoic membrane (CAM) assays were utilized to evaluate the effect of CPT1A on the pro-angiogenic properties of BC. Subsequently, untargeted metabolomics was employed to identify specific metabolic changes in supernatants with and without CPT1A expression and verified by functional recovery experiments. Finally, the prognostic significance of CPT1A and the vascular marker VEGF in BC tissues was evaluated using tissue microarrays and public databases. CPT1A overexpression significantly enhanced cell proliferation, motility, and angiogenesis via activating the FAO metabolic pathway, as demonstrated by both in vivo and in vitro experiments. Mechanistically, CPT1A regulates the ubiquitination level of hypoxia-inducible factor-1α (HIF-1α), which directly binds to the CPT1A promoter. Mutations at the 63-74 and 434-445 regions significantly reduced CPT1A promoter activity, indicating that these sites are critical for its transcriptional regulation. Ultimately, this interaction creates a reinforcing feedback loop between CPT1A and HIF-1α. Subsequently, this feedback loop alters changes in extracellular L-ascorbic acid (LAA) levels. Interestingly, LAA affects ROS homeostasis through the Nrf2/NQO1 pathway, specifically influencing angiogenesis in BC and HUVECs, while having no significant effect on their proliferation or EMT process. Moreover, increased expression levels of CPT1A and vascular endothelial growth factor (VEGF) were significantly associated with lymph node metastasis and adverse outcomes in BC patients. The CPT1A/HIF-1α positive feedback loop critically regulates angiogenesis through activation of the Nrf2/NQO1 pathway, modulated by LAA. These findings highlight CPT1A and VEGF as promising therapeutic targets and prognostic biomarkers for angiogenesis in BC.